Switch theme
Sign up to access all valuation multiples
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
2006
66
LTM Revenue $4.4M
Last FY EBITDA -$15.4M
$56.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Icecure Medical has a last 12-month revenue (LTM) of $4.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Icecure Medical achieved revenue of $3.3M and an EBITDA of -$15.4M.
Icecure Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Icecure Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.4M | XXX | $3.3M | XXX | XXX | XXX |
| Gross Profit | $2.1M | XXX | $1.5M | XXX | XXX | XXX |
| Gross Margin | 47% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$15.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -467% | XXX | XXX | XXX |
| EBIT | -$14.5M | XXX | -$15.7M | XXX | XXX | XXX |
| EBIT Margin | -331% | XXX | -477% | XXX | XXX | XXX |
| Net Profit | -$14.3M | XXX | -$15.3M | XXX | XXX | XXX |
| Net Margin | -326% | XXX | -465% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Icecure Medical's stock price is $1.
Icecure Medical has current market cap of $61.8M, and EV of $56.2M.
See Icecure Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $56.2M | $61.8M | XXX | XXX | XXX | XXX | $-0.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Icecure Medical has market cap of $61.8M and EV of $56.2M.
Icecure Medical's trades at 17.1x EV/Revenue multiple, and -3.7x EV/EBITDA.
Equity research analysts estimate Icecure Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Icecure Medical has a P/E ratio of -4.3x.
See valuation multiples for Icecure Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $61.8M | XXX | $61.8M | XXX | XXX | XXX |
| EV (current) | $56.2M | XXX | $56.2M | XXX | XXX | XXX |
| EV/Revenue | 12.8x | XXX | 17.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.7x | XXX | XXX | XXX |
| EV/EBIT | -3.9x | XXX | -3.6x | XXX | XXX | XXX |
| EV/Gross Profit | 27.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.3x | XXX | -4.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIcecure Medical's last 12 month revenue growth is 105%
Icecure Medical's revenue per employee in the last FY averaged $50K, while opex per employee averaged $0.3M for the same period.
Icecure Medical's rule of 40 is -368% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Icecure Medical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Icecure Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 105% | XXX | 101% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -467% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -368% | XXX | -362% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $50K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 216% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 521% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Icecure Medical acquired XXX companies to date.
Last acquisition by Icecure Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Icecure Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Icecure Medical founded? | Icecure Medical was founded in 2006. |
| Where is Icecure Medical headquartered? | Icecure Medical is headquartered in United States of America. |
| How many employees does Icecure Medical have? | As of today, Icecure Medical has 66 employees. |
| Who is the CEO of Icecure Medical? | Icecure Medical's CEO is Mr. Eyal Shamir. |
| Is Icecure Medical publicy listed? | Yes, Icecure Medical is a public company listed on NAS. |
| What is the stock symbol of Icecure Medical? | Icecure Medical trades under ICCM ticker. |
| When did Icecure Medical go public? | Icecure Medical went public in 2013. |
| Who are competitors of Icecure Medical? | Similar companies to Icecure Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Icecure Medical? | Icecure Medical's current market cap is $61.8M |
| What is the current revenue of Icecure Medical? | Icecure Medical's last 12 months revenue is $4.4M. |
| What is the current revenue growth of Icecure Medical? | Icecure Medical revenue growth (NTM/LTM) is 105%. |
| What is the current EV/Revenue multiple of Icecure Medical? | Current revenue multiple of Icecure Medical is 12.8x. |
| Is Icecure Medical profitable? | Yes, Icecure Medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
